DICON COVID-19 Weekly Digest 5/11/2020
Sonali Advani, MBBS, MPH, Elizabeth Dodds-Ashley, PharmD, MHS, Dan Sexton, MD

What’s New on DICON COVID Resources?
Upcoming COVID-19 DICON FAQs
- Can we rely on preoperative testing for SARS-COV-2 to safely restart elective procedures?
- How can we reprocess “single use” GlideScope Blades during COVID-19 pandemic?

Duke Updates:
Many Duke surgery centers and clinics resumed on-site care on 5/4/2020

Document updates
- Life Support FAQs
- Ability to Work/Return to Work for Healthcare Providers
- CDC Guidance: Employee Risk Assessment for COVID-19 Exposure
- Criteria for Discontinuation of Special Airborne Contact Isolation
- Appropriate PPE during COVID-19 Response

Notable articles related to SARS-COV-2 Epidemiology, Transmission and Infection Prevention:
MMWR:
- Public Health Response to COVID-19 Cases in Correctional and Detention Facilities — Louisiana, March–April 2020

JAMA:
- Surgery in a Time of Uncertainty: A Need for Universal Respiratory Precautions in the Operating Room
- The Ethics of COVID-19 Immunity-Based Licenses (“Immunity Passports”)
- Privileges and Immunity Certification During the COVID-19 Pandemic
- Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons with Wuhan and Guangzhou, China

Annals:
- Health Care Supply Chains: COVID-19 Challenges and Pressing Actions
- Coronavirus Disease 2019 (COVID-19): Protecting Hospitals from the Invisible

CID:
- COVID-19 Testing, Epidemic Features, Hospital Outcomes, and Household Prevalence, New York State—March 2020
• Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s Diagnostics Committee
• Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19

Other Journals:
• Rapid implementation of mobile technology for real-time epidemiology of COVID-19

Regulatory updates:
• FAQ document regarding new COVID reporting requirements for nursing homes.
• CMS has pre-posted an interim final rule with changes in response to COVID- the comment period will be open for 60 days from official posting (currently posting is scheduled for tomorrow). You can see the pre-release PDF at this link.
• The FDA has modified the Emergency Use Authorization for antibody tests- these must undergo FDA review (any tests released without this FDA review, need to seek review within 10 days)- details can be found on this site.

News Updates:
• Roche has been granted emergency authorization for an antibody test on the Cobas platform.
• IDSA letter calling for more transparent process for Remdesivir distribution.
• Mass testing in Mission District of San Francisco in a press release.
• Another vaccine study in humans began yesterday- here is a summary.